[1. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocar-dial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454-71.10.1016/j.jacc.2015.02.03225857912]Search in Google Scholar
[2. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk. World J Cardiol 2017;9(5):407-15.10.4330/wjc.v9.i5.407544240828603587]Search in Google Scholar
[3. Greene SJ, Sabbah HN, Butler J, Voors AA, Albrecht-Küpper BE, Düngen HD, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev 2016;21(1):95-102.10.1007/s10741-015-9522-726701329]Search in Google Scholar
[4. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017;38(11):774-84.]Search in Google Scholar
[5. Da Silva JS, Gabriel-Costa D, Sudo RT, Wang H, Groban L, Ferraz EB, et al. Adenosine A2A receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Des Devel Ther 2017;11:553-62.10.2147/DDDT.S113289534599728293100]Search in Google Scholar
[6. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ 2000;320(7228):167-70.10.1136/bmj.320.7228.167112874710634740]Search in Google Scholar
[7. Puhl SL, Kazakov A, Müller A, Fries P, Wagner DR, Böhm M, et al. Adeno-sine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to α1-adrenoceptor stimulation in vivo. Br J Pharmacol 2016;173(1):88-102.10.1111/bph.13339481337926406609]Search in Google Scholar
[8. Pang T, Gan XT, Freeman DJ, Cook MA, Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine -induced hyper-trophy in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2010;298(2):H545-53.10.1152/ajpheart.00417.200919966059]Search in Google Scholar
[9. Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, et al. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure -overload model. Circ Res 2003;93(8):759-66.10.1161/01.RES.0000094744.88220.6212970111]Search in Google Scholar
[10. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, et al. Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure -overloaded left ventricle. Circulation 2008;118(17):1713-21.10.1161/CIRCULATIONAHA.108.788307280305018838560]Search in Google Scholar
[11. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, et al. Chronic therapy with a partial adenosine A1 -receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 2013;6(3):563-71.10.1161/CIRCHEARTFAILURE.112.000208379014123564604]Search in Google Scholar
[12. Dinh W, Albrecht-Küpper B, Gheorghiade M, Voors AA, van der Laan M, Sabbah HN. Partial adenosine A1 agonist in heart failure. Handb Exp Pharmacol 2017;243:177-203.10.1007/164_2016_8327770217]Search in Google Scholar
[13. Baltos JA, Vecchio EA, Harris MA, Qin CX, Ritchie RH, Christopoulos A, et al. Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. Biochem Pharmacol 2017;135:79-89.10.1016/j.bcp.2017.03.01428344125]Search in Google Scholar
[14. Meibom D, Albrecht-Küpper B, Diedrichs N, Hübsch W, Kast R, Krämer T, et al. Neladenoson bialanate hydrochloride: a prodrug of a partial aden-osine A1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 2017;12(10):728-37.10.1002/cmdc.20170015128488817]Search in Google Scholar
[15. Voors AA, Düngen HD, Senni M, Nodari S, Agostoni P, Ponikowski P, et al. Safety and tolerability of neladenoson bialanate, a novel oral partial aden-osine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharmacol 2017;57(4):440-51.10.1002/jcph.82827624622]Search in Google Scholar
[16. Da Silva JS, Pereira SL, Maia Rdo C, Landgraf SS, Caruso -Neves C, Küm-merle AE, et al. N -acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle. Life Sci 2014;94(1):30-6.10.1016/j.lfs.2013.11.01224269214]Search in Google Scholar
[17. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;16(11):1655-73.10.1093/europace/euu20825172845]Search in Google Scholar
[18. Bhar-Amato J, Davies W, Agarwal S. Ventricular arrhythmia after acute myocardial infarction: ‘The perfect storm’. Arrhythm Electrophysiol Rev 2017;6(3):134-9.10.15420/aer.2017.24.1561073129018522]Search in Google Scholar
[19. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016;106(1):62-9.10.5935/abc.20160005472859726647721]Search in Google Scholar
[20. Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol 2016;91:114-212.10.1016/j.yjmcc.2015.12.024476439526739214]Search in Google Scholar
[21. Szentmiklosi AJ, Galajda Z, Cseppento Á, Gesztelyi R, Susán Z, Hegyi B, et al. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. Curr Pharm Des 2015;21(8):965-76.10.2174/138161282066614102910034625354187]Search in Google Scholar
[22. Lerman BB. Ventricular tachycardia: mechanistic insights derived from adenosine. Circ Arrhythm Electrophysiol 2015;8(2):483-91.10.1161/CIRCEP.115.00169325900991]Search in Google Scholar
[23. Zhang H, Zhong H, Everett TH 4th, Wilson E, Chang R, Zeng D, et al. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm 2014;11(1):101-9.10.1016/j.hrthm.2013.10.02324120874]Search in Google Scholar
[24. Vecchio EA, White PJ, May LT. Targeting adenosine receptors for the treatment of cardiac fibrosis. Front Pharmacol 2017;8:243.10.3389/fphar.2017.00243541834028529484]Search in Google Scholar
[25. Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O, Okada K, et al. Long -term stimulation of adenosine A2B receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006;114(18):1923-32.10.1161/CIRCULATIONAHA.106.63008717043167]Search in Google Scholar
[26. Toldo S, Zhong H, Mezzaroma E, Van Tassell BW, Kannan H, Zeng D, et al. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther 2012;343(3):587-95.10.1124/jpet.111.19128822923737]Search in Google Scholar